SL Science reports tumor eradication by day 26
SL Science (NASDAQ:SLBT) presented preclinical glioblastoma data showing complete tumor eradication by day 26 at an 8:1 immune-cell-to-cancer-cell ratio.
Todas as matérias desta categoria, das mais recentes às mais antigas.
SL Science (NASDAQ:SLBT) presented preclinical glioblastoma data showing complete tumor eradication by day 26 at an 8:1 immune-cell-to-cancer-cell ratio.
Cloudastructure (NASDAQ:CSAI) reported Q1 revenue of $1.315 million, up 78%, while gross profit increased 115% to $710,000.
Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European approval for Boey across 30 countries, with effects observed from eight hours.
Jeffrey Currie, chief strategy officer at Altis Partners, says "crude oil prices are the noise, product prices are the signal," as he explains why the global oil market has moved from deficit to shortage.
Kimbell Royalty Partners (NYSE:KRP) agreed to acquire multi-basin royalty interests for $215.4 million, adding expected Q3 production of 2,347 boe/d.
Intuitive Surgical (NASDAQ:ISRG) shares fell more than 12% after the company maintained 13.5%–15.5% procedure-growth guidance and flagged insurance pressure.
SpaceX (NASDAQ:SPCX) shares fell 3.5% to $126.58 premarket after an engine failure aborted Starship’s 13th test before liftoff.
"I will be a pro-business leader of the Labour Party, as I was a pro-business mayor of Greater Manchester," Andy Burnham says in his first speech since formally becoming leader of the Labour Party. He will take over as prime minister from Keir Starmer on Monday.
Veradermics (NYSE:MANE) presented age-based VDPHL01 data from Study ‘302,’ a 519-patient trial in males with mild-to-moderate pattern hair loss.
Solstice Advanced Materials (NASDAQ:SOLS) declared a regular quarterly dividend of $0.075 per common share, payable on September 10, 2026.
Andy Burnham delivers a speech after he is officially named leader of the UK's Labour Party. "This is a proud moment," he says. Burnham is set to become the UK's next prime minister.
Kalaris Therapeutics (NASDAQ:KLRS) reported expanded Phase 1a TH103 data from 20 patients, with plasma exposure up to 53-fold below leading anti-VEGF agents.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade